|Role this area should play in the mHealth space|
Although the role of remote monitoring of patients with long-term conditions is well regarded, robust evidence of the health outcomes benefit, impact on health services including cost benefit are difficult to find. This kind of evidence is critical for decision-makers, to justify investments in mobile health interventions for long-term conditions.
|Current challenges and limitations|
|What benefit could this bring to adopters of this innovation?|
|Evidence of health and financial benefits from mHealth solutions in long-term conditions can help Hub users when constructing business cases for future programmes. It may not be necessary for the evidence to be in the precise disease area being considered for a new programme, if a portfolio of similar convincing cases can give confidence and guide how a new business case could be framed.|
|How does it contribute to major EU policy priorities? (e.g. EHDS, COVID-19, DTHC etc.)|
|Non-communicable diseases still represent the greatest healthcare capacity and cost burden across Europe, set to increase with an ageing society. Methods of reducing healthcare service utilisation need to be promoted, and benefit from European level collaboration on sharing solutions and evidence.
If the use of mHealth, as illustrated here, lead to fewer hospitalisations and in-person clinic contacts, this will be of immediate value in response to COVID-19, when health systems are trying to reduce in person contacts and maximise hospital bed availability.
No post found
|What is on the horizon?|
|More studies in progress that will help strengthen the evidence base of health outcomes benefit and cost effectiveness benefit. They will also help to confirm which heart failure parameters are of greatest importance to measure on a regular basis.|